Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Mutations in the gene encoding LRRK2 (leucine-rich repeat kinase 2) were first identified in 2004 and have since been shown to be the single most common cause of inherited Parkinson's disease. The protein is a large GTP-regulated serine/threonine kinase that additionally contains several protein-protein interaction domains. In the present review, we discuss three important, but unresolved, questions concerning LRRK2. We first ask: what is the normal function of LRRK2? Related to this, we discuss the evidence of LRRK2 activity as a GTPase and as a kinase and the available data on protein-protein interactions. Next we raise the question of how mutations affect LRRK2 function, focusing on some slightly controversial results related to the kinase activity of the protein in a variety of in vitro systems. Finally, we discuss what the possible mechanisms are for LRRK2-mediated neurotoxicity, in the context of known activities of the protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Because we know that one of the major proteins found in Lewy bodies, a-synuclein, is also a gene for PD when mutated (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004) or if expression is increased without any sequence variants (Singleton et al., 2003; Chartier-Harlin et al.,…”
BackgroundThe protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“…also a gene for PD when mutated (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004) or if expression is increased without any sequence variants (Singleton et al., 2003; Chartier-Harlin et al., 2004), a-synuclein fulfils the requirements for a toxic agent in PD (Cookson, 2005).”
BackgroundSelf-citationAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Cited by
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
“netic cause of typical PD is mutations in the gene for leucine rich repeat kinase 2 (LRRK2).(42) The recent de-”
BackgroundKinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
Self-citationAxon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.538 · Cited by 417
Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405
“encodes a multi-domain protein belonging to the ROCO family characterized by a Ras of Complex (ROC) GTPase domain and a C-terminal of ROC (COR) domain in conjunction with a kinase domain with similarity to RIP kinases”
BackgroundKinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 372
Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004485 · Cited by 353
Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., & Yue, Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5604-09.2010 · Cited by 341
LRRK2 Controls an EndoA Phosphorylation Cycle in Synaptic Endocytosis
Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.-J., Morais, V. A., Vilain, S., Haddad, D., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.022 · Cited by 337
Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R. F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S. E., Bulman, D. E., Scherzer, C. R., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0653-2 · Cited by 283
LRRK2 levels in immune cells are increased in Parkinson’s disease
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0010-8 · Cited by 279
Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.010 · Cited by 275
Tonges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., Bahr, M., Weishaupt, J. H., & Lingor, P. (2012) · Brain · doi:10.1093/brain/aws254 · Cited by 176
“This axon-accentuated pathology is also seen in mouse models harbouring mutations of leucine-rich repeat kinase 2 (LRRK2), a protein that is frequently mutated in inherited forms of Parkinson’s disease (Greggio and Cookson, 2009).”
BackgroundLRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism
Arranz, A. M., Delbroek, L., Van Kolen, K., Guimarães, M. R., Mandemakers, W., Daneels, G., Matta, S., Calafate, S., Shaban, H., Baatsen, P., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.158196 · Cited by 111
Genetic variability at the PARK16 locus
Tucci, A., Nalls, M. A., Houlden, H., Revesz, T., Singleton, A. B., Wood, N. W., Hardy, J., & Paisán-Ruiz, C. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.125 · Cited by 81
Leucine Rich Repeat Proteins: Sequences, Mutations, Structures and Diseases
Matsushima, N., Takatsuka, S., Miyashita, H., & Kretsinger, R. H. (2019) · Protein & Peptide Letters · doi:10.2174/0929866526666181208170027 · Cited by 73
Small-Molecule Inhibitors of LRRK2
Hatcher, J. M., Choi, H. G., Alessi, D. R., & Gray, N. S. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_13 · Cited by 39
The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells
Hongge, L., Kexin, G., Xiaojie, M., Nian, X., & Jinsha, H. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0312-9 · Cited by 36
Fernández, B., Lara Ordóñez, A. J., Fdez, E., Mutez, E., Comptdaer, T., Leghay, C., Kreisler, A., Simonin, C., Vandewynckel, L., Defebvre, L., et al. (2019) · Biochemical Journal · doi:10.1042/bcj20190315 · Cited by 33
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Decoding Parkinson’s Disease Pathogenesis: The Role of Deregulated mRNA Translation
Martin, I. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150738 · Cited by 23
“LRRK2 (leucine-rich repeat kinase 2) is a large multi-domain protein with enzymatic RAS-like GTPase and kinase domains in which numerous disease-linked mutations are clustered [23].”
Background
Metadata
- Authors
- Greggio, E., & Cookson, M. R.
- Venue
- ASN Neuro
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 1
- Issue
- 1
- ISSN
- 1759-0914 (ISSN-L)
- OpenAlex
- W2072216745
- Cited by
- 272
- References
- 91
- FWCI
- 18.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.